Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule
- 1 June 1982
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 18 (6), 519-522
- https://doi.org/10.1016/0277-5379(82)90220-6
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Drug Dependent Red Cell Antibodies and Intravascular Haemolysis Occurring in Patients Treated with 9 Hydroxy‐Methyl‐EllipticiniumBritish Journal of Haematology, 1980
- Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264-137) in advanced human cancersEuropean Journal of Cancer (1965), 1978